We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+37.8%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$198M
AUM Growth
+$69.6M
Cap. Flow
+$26.9M
Cap. Flow %
13.6%
Top 10 Hldgs %
58.47%
Holding
43
New
13
Increased
10
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$4.93M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$4.58M
3
GNMX
Aevi Genomic Medicine Inc
GNMX
+$4.2M
4
KITE
Kite Pharma, Inc.
KITE
+$3.2M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$2.94M

Top Sells

Rank Stock Value
1
NSPR icon
InspireMD
NSPR
+$4.59M
2
BIND
BIND THERAPEUTICS INC
BIND
+$3.87M
3
PRTA icon
Prothena Corp
PRTA
+$3.48M
4
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.4M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$1.92M

Sector Composition

Rank Sector Weight
1 Healthcare 91.91%
2 Miscellaneous 8.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
1
DELISTED
Chimerix, Inc.
CMRX
$32.4M 16.38%
805,000
+50,000
+7% +$1.69M
AGIO icon
2
Agios Pharmaceuticals
AGIO
$2.05B
$12.7M 6.43%
113,500
– –
CEMP
3
DELISTED
Cempra, Inc.
CEMP
$11.9M 6%
504,800
– –
TVTX icon
4
Travere Therapeutics
TVTX
$6.36B
$11.3M 5.69%
920,000
-80,000
-8% -$828K
ARIA
5
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$10.5M 5.29%
1,525,000
+25,000
+2% +$156K
PCYC
6
DELISTED
PHARMACYCLICS INC
PCYC
$10.4M 5.25%
85,000
– –
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
$7.84M 3.96%
140,000
– –
TTPH
8
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$7.53M 3.81%
9,485
+1,000
+12% +$538K
GERN icon
9
Geron
GERN
$983M
$5.93M 3%
1,825,000
+1,005,000
+123% +$2.78M
ARAV
10
DELISTED
Aravive, Inc. Common Stock
ARAV
$5.28M 2.67%
+39,167
New +$4.58M
KYNB
11
Kyntra Bio
KYNB
$32.4M
$5.23M 2.64%
+7,654
New +$4.93M
INSY
12
DELISTED
Insys Therapeutics, Inc.
INSY
$5.17M 2.61%
245,000
– –
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$2.59B
$4.66M 2.35%
106,200
+21,200
+25% +$971K
GNMK
14
DELISTED
GenMark Diagnostics, Inc
GNMK
$4.56M 2.3%
335,000
-215,000
-39% -$2.4M
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.49M 2.27%
100,000
+65,000
+186% +$2.73M
KITE
16
DELISTED
Kite Pharma, Inc.
KITE
$4.38M 2.21%
+76,000
New +$3.2M
CDXS icon
17
Codexis
CDXS
$182M
$4.34M 2.2%
1,724,000
+34,000
+2% +$81.1K
GNMX
18
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.3M 2.17%
+850,000
New +$4.2M
HROW icon
19
Harrow
HROW
$1.44B
$4.2M 2.12%
560,000
+57,500
+11% +$467K
CSII
20
DELISTED
Cardiovascular Systems, Inc.
CSII
$3.76M 1.9%
125,000
– –
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$3.51M 1.77%
+205,000
New +$2.93M
LAB icon
22
Standard BioTools
LAB
$256M
$3.2M 1.62%
95,000
+28,000
+42% +$793K
PRTK
23
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.08M 1.56%
+80,000
New +$1.91M
TRIL
24
DELISTED
Trillium Therapeutics Inc.
TRIL
$3M 1.52%
+333,333
New +$2.6M
SUPN icon
25
Supernus Pharmaceuticals
SUPN
$2.57B
$2.9M 1.47%
+350,000
New +$2.94M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2014 Portfolio in Review

As of Q4 2014, Opaleye Management held 43 positions worth $198M, up 54% from $128M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Opaleye Management deployed $26.9M of net new capital in Q4 2014, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was Kyntra Bio: 7,654 shares worth $5.23M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was GenMark Diagnostics, Inc, an estimated $2.4M trimmed.

  • Opaleye Management's largest Q4 2014 buy was Kyntra Bio: 7,654 shares worth $5.23M.
  • Opaleye Management added most to Geron in Q4 2014, an estimated $2.78M increase.
  • Opaleye Management's biggest Q4 2014 reduction was GenMark Diagnostics, Inc, cutting an estimated $2.4M.
  • Opaleye Management fully exited BIND THERAPEUTICS INC in Q4 2014, selling an estimated $3.87M.
  • Opaleye Management's ten largest holdings make up 58% of its $198M portfolio in Q4 2014.
  • Opaleye Management opened 13 new positions and closed 6 in Q4 2014.
  • Opaleye Management's portfolio value rose 54% quarter-over-quarter to $198M.

Based on Opaleye Management's 13F filing for Q4 2014, filed 13 Feb 2015.